Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 10 June 2022, including: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the MS market; and a look at Aduhelm one year later.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm" - Scrip, 5 Jun, 2022.)
(Also see "Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field" - Scrip, 6 Jun, 2022.)
(Also see "BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition" - Scrip, 3 Jun, 2022.)
(Also see "MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space" - Scrip, 3 Jun, 2022.)
(Also see "How Biogen’s Aduhelm Bet Became A Commercial Bust" - Scrip, 6 Jun, 2022.)